bioRxivImmunologyPreprint
IL-34 empowers regulatory T cells with novel non-canonical function to safeguard brain barrier integrity during neuro-inflammation.
Lien Van HoeckeiD, Janne VerreyckeniD, Lore Van AckeriD, Laura Amelinck, Junhua XieiD, Jonas CasteleiniD, Elien Van WonterghemiD, Griet Van ImschootiD, Marlies BurgelmaniD, Sarah VanherleiD, Ilse DewachteriD, Paulien BaeteniD, Bieke BrouxiD, Roosmarijn E. VandenbrouckeiD
Abstract
In efforts to find reparative strategies for brain damage, brain-associated regulatory T cells (Tregs) have gained increasing attention in recent years. Beyond their textbook immunoregulatory function, Tregs have emerged as key players in the response to brain trauma and the restoration of damaged brain tissue. Here, we are the first to describe a novel, non-canonical function of Tregs in maintaining the sealing capacity of both the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier. Moreover, we identified the cytokine IL-34 as a critical determinant in this newly unveiled Treg function. Mechanistically, IL-34 exerts its influence by modulating the expression and localization of the tight junction protein ZO-1 in both BBB endothelial cells and choroid plexus epithelial cells, thereby reinforcing the strength of the brain barriers. Given the well-established notion of leaky brain barriers and the involvement of immunological components in neurological diseases such as Alzheimers disease (AD) and multiple sclerosis (MS), we further demonstrate diminished IL-34 expression in Tregs derived from patients with relapsing-remitting MS (RR-MS) and patients with AD and even mild cognitive impairment (MCI). Remarkably, our study reveals the potential of IL-34 treatment in reinstating the integrity of brain barriers within murine models mimicking these neurological disorders. These ground-breaking findings shed light on the intricate relationship between Tregs, IL-34, and the integrity of brain barriers. They offer novel avenues for therapeutic approaches to ameliorate brain barrier dysfunction in the context of neurological disorders.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation
L. Yshii, E. Pasciuto, … A. Liston·bioRxiv·Feb 28, 2022
- Transthyretin Contributes to Hippocampal Blood-Brain Barrier Recovery Following Intestinal Inflammation, with Reduced Expression in Alzheimer's Disease
Zhi Xu, Jun Chen, … Jing Zhang·bioRxiv·Sep 4, 2026
- The meninges host a unique compartment of regulatory T cells that bulwarks adult hippocampal neurogenesis
Miguel Marin-Rodero, Elisa Cintado, … Diane J. Mathis·Science ImmunologyPeer-reviewed·Jan 28, 2025
- Interleukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection
Shun Li, Florian olde Heuvel, … Francesco Roselli·bioRxiv·Dec 1, 2021
- Rapamycin rescues loss-of-function in blood-brain barrier-interacting regulatory T cells
- TLR4-pathway impairs synaptic number and cerebrovascular functions through astrocyte activation following traumatic brain injury
Juliana M. Rosa, Víctor Farré‐Alins, … Javier Egea·British Journal of PharmacologyPeer-reviewed·Apr 8, 2021